Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Fred Aslan M.D. | President, CEO & Director | 917.3k | -- | 1976 |
| Dr. Peter Flynn Ph.D. | Co-Founder & Strategic Advisor | 499.37k | -- | 1974 |
| Ms. Jennifer Kinsbruner Bush Esq., J.D. | Executive VP, COO, Chief Legal Officer, Corporate Secretary & Compliance Officer | 630.31k | -- | 1975 |
| Mr. Christopher P. Horan | Chief Technical Operations Officer | 612.23k | -- | 1968 |
| Ms. Neha Krishnamohan | CFO & Executive VP of Corporate Development | -- | -- | 1988 |
| Dr. Thorsten Graef M.D., Ph.D. | Chief Medical Officer | -- | -- | 1977 |
| Dr. Heather Raymon Ph.D. | Senior Vice President of Research & Early Development | -- | -- | 1964 |
| Dr. David Moriarty Ph.D. | Senior VP of Clinical Operations | -- | -- | -- |
| Mr. Benjamin Dewees | Senior Vice President of Regulatory Affairs | -- | -- | -- |
| Mr. Feng Xu | Senior Vice President of Biometrics | -- | -- | -- |
Artiva Biotherapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 89
Description
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/ microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of solid tumors; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. The company was incorporated in 2019 and is headquartered in San Diego, California.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
July 16, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
July 5, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission